ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 905 for:    EVALUATE HF
Previous Study | Return to List | Next Study

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (EVALUATE-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02874794
Recruitment Status : Recruiting
First Posted : August 22, 2016
Last Update Posted : November 17, 2017
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.

Condition or disease Intervention/treatment Phase
Heart Failure and Reduced Ejection Fraction Drug: LCZ696 (sacubitril/valsartan) Drug: Enalapril Drug: Placebo of Enalapril Drug: Placebo of LCZ696 Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 432 participants
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)
Actual Study Start Date : August 17, 2016
Estimated Primary Completion Date : March 7, 2019
Estimated Study Completion Date : March 7, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: LCZ696 (sacubitril/valsartan)
minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
Drug: LCZ696 (sacubitril/valsartan)
24/26mg, 49/51mg and 97/103mg oral, tablets.
Other Name: LCZ696

Drug: Placebo of Enalapril
matching placebo (2.5mg, 5mg and 10mg) oral, tablets

Active Comparator: Enalapril
minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
Drug: Enalapril
2.5mg, 5mg, and 10mg, oral, tablets

Drug: Placebo of LCZ696
matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets




Primary Outcome Measures :
  1. Change from baseline in aortic characteristic impedance at week 12 [ Time Frame: Baseline, Week 12 ]
    Aortic characteristic impedance, Zc, is the ratio of the change in pressure (dP)produced by a given change in flow (dQ) in early systole, i.e., Zc = dP/dQ. Zc is related directly to aortic wall stiffness and inversely to lumen area.


Secondary Outcome Measures :
  1. Pearson correlation coefficient between change from baseline in aortic characteristic impedance and biomarker levels such as B-type natriuretic peptide (BNP) during both trough and 4 hours post-dose at Week 4 [ Time Frame: Pre-dose and 4 hours post dose at week 4 ]
    Pearson correlation coefficients between changes from baseline in aortic characteristic impedance and biomarker levels such as BNP during both trough and 4 hours post-dose at Week 4 will be calculated by treatment.

  2. Pearson correlation coefficient between change from baseline in aortic characteristic impedance and biomarker levels such as U-cGMP/U-creatinine during both trough and 4 hours post-dose at Week 4 [ Time Frame: pre-dose and 4 hours post dose at week 4 ]
    Pearson correlation coefficient between changes from baseline in aortic characteristic impedance and biomarker levels such as U-cGMP/U-creatinine during both trough and 4 hours post-dose at Week 4 will be calculated by treatment.

  3. Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) [ Time Frame: Baseline, Week 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of HTN and one of the following at BOTH screening and pre-randomization:

    1. SBP >105 mm Hg on antihypertensive medication.
    2. SBP >/= 140 mm Hg and NOT on antihypertensive medication.
  • NYHA class I-III heart failure and with reduced ejection fraction </= 40%.
  • On stable doses of treatment with guideline-directed therapy, other than ACEis and ARBs prior to randomization.

    1. If the patient is currently taking an ACEi, a 36-hour washout is required prior to randomization (Visit 2).
    2. If the patient is currently taking an ARB, they must discontinue the ARB before initiation of study treatment however washout is not required.
  • On an optimal medical regiment of diuretics and background medications to effectively treat co-morbidities such as HTN, DM, and coronary artery disease.

Key Exclusion Criteria:

  • History of hypersensitivity to any of the study drigs, including history of hypersensitivity to drugs of similar chemical classes, or allergy to ACEis, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drugs.
  • Previous history of intolerance to sacubitril and valsartan, ACEi or ARB standard of care doses despite appropriate and gradual up-titration.
  • History of angioedema, drug-related or otherwise.
  • Requirement of treatment with both ACE inhibitor and ARB.
  • Current or prior treatment with sacubitril and valsartan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02874794


Contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals

  Show 67 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02874794     History of Changes
Other Study ID Numbers: CLCZ696BUS08
First Posted: August 22, 2016    Key Record Dates
Last Update Posted: November 17, 2017
Last Verified: November 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Heart Failure
Reduced Ejection Fraction
Central Aortic Stiffness
Vascular
Echocardiogram

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Valsartan
Enalapril
Enalaprilat
LCZ 696
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors